^177Lu标记放射性药物临床研究进展

The Progress in Clinical Research of ^(177)Lu Labeled Radiopharmaceuticals

^(177)Lu由于具有优良的放射性物理特性,在肿瘤治疗领域具有明显优势,临床研究者对其开展了大量临床研究工作。^(177)Lu标记的生长抑素类似物——^(177)Lu-DOTATATE已在美国和欧盟获批。本文对六种^(177)Lu标记的放射性药物包括其标记的多肽、单克隆抗体和化合物的临床研究进展进行综述,它们有的已被批准临床试验有的还未被批注。临床数据显示本文列出的部分药物治疗相应癌症具有较好的安全性,对延长患者生存期,提高患者的生存质量具有一定的效果。部分药物使用是安全的,但其具体临床疗效还需跟多的临床试验数据来支持。我们期待有更多的^(177)Lu标记药物能尽早进入市场。

177Lu has great advantages in the field of tumor therapy because of its excellent radioactive physical properties.A large number of clinical studies have been carried out by clinical researchers on 177Lu labeled radiopharmaceuticals.177Lu-labeled somatostatin analogue 177Lu-DOTATATE has been approved both in the United States and the European Union.This article reviews the clinical research progress of six 177Lu-labeled radiopharmaceuticals including their labeled peptides,monoclonal antibodies and compounds.Some of them have been approved for clinical trials and others have not been endorsed.Clinical data showed that some of the drugs listed in this article have relatively good safety,and have promising effects on prolonging the survival of patients and improving patient's quality of life.Some drug usage has been proved to be safe,but its specific clinical efficacy needs to be supported by more clinical trial data.We are expecting more 177Lu labeled drugs to enter the market in the near future.